Grove Instruments Inc., a Worcester, MA –based medical device company developing a non invasive glucometer, has raised $6m in Series B financing.
Backers included new investors from the greater Boston area and existing shareholders.
Led by CEO Arthur Combs, Grove is developing a noninvasive glucometer with the potential to exceed the ISO standard for blood glucose meters. The company’s patented technology is based on the seminal concept of the Optical Bridge and is unique among all NIR spectroscopic approaches to noninvasive blood glucose determination.
Grove recently added 2 recognized leaders in diabetes care and research, William Tamborlane, MD of Yale and David Harlan, MD of the University of Massachusetts and formerly of NIH NIDDK, to its Scientific Advisory Board.
Most recently, Craig Mello, Ph D, Nobel Laureate and molecular biologist joined the company’s Board of Directors.